Evidence map›Paper›PMID 36569881›Full record

Trial reportFrontiers in immunology2022

Sintilimab plus autologous NK cells as second-line treatment for advanced non-small-cell lung cancer previous treated with platinum-containing chemotherapy.

Lin Jia, Naifei Chen, Xiao Chen, Chao Niu, Ziling Liu, Kewei Ma, Nanya Wang, Lei Yang, Yuguang Zhao, Wei Song and 10 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03958097 (A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer), which is not on this map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03958097 phase2completednot on this map

A Pilot Study of NK Cell Combined With PD-1 Antibody as Second Line Therapy for Advanced Driver Mutation Negative Non-small Cell Lung Cancer

TypeinterventionalSponsorThe First Hospital of Jilin UniversityRan2019 to 2021Enrolled20ConditionsNon-small Cell Lung CancerArmsNK cell and PD-1 antibody
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
  16. Reprogramming natural killer cells for cancer therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lin JiaCancer Center, The First Hospital of Jilin University, Changchun, China.
Naifei ChenCancer Center, The First Hospital of Jilin University, Changchun, China.
Xiao ChenCancer Center, The First Hospital of Jilin University, Changchun, China.
Chao NiuCancer Center, The First Hospital of Jilin University, Changchun, China.
Ziling LiuCancer Center, The First Hospital of Jilin University, Changchun, China.
Kewei MaCancer Center, The First Hospital of Jilin University, Changchun, China.
Nanya WangCancer Center, The First Hospital of Jilin University, Changchun, China.
Lei YangCancer Center, The First Hospital of Jilin University, Changchun, China.
Yuguang ZhaoCancer Center, The First Hospital of Jilin University, Changchun, China.
Wei SongCancer Center, The First Hospital of Jilin University, Changchun, China.
Jin LuCancer Center, The First Hospital of Jilin University, Changchun, China.
Chen ChenCancer Center, The First Hospital of Jilin University, Changchun, China.
Xiaofeng CongCancer Center, The First Hospital of Jilin University, Changchun, China.
Xu WangCancer Center, The First Hospital of Jilin University, Changchun, China.
Yinghui XuCancer Center, The First Hospital of Jilin University, Changchun, China.
Guozhen CuiCancer Center, The First Hospital of Jilin University, Changchun, China.
Zengguang LiuCancer Center, The First Hospital of Jilin University, Changchun, China.
Rongrong ChenDepartment of Medical Center, GenePlus-Beijing, Beijing, China.
Wei LiCancer Center, The First Hospital of Jilin University, Changchun, China.
Jiuwei CuiCancer Center, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This pilot study (NCT03958097; https://www.clinicaltrials.gov/ct2/show/NCT03958097) was aimed to evaluate the efficacy and safety of PD-1 antibody combined autologous NK cells in the treatment of patients with stage IIIB/IIIC or IV non-small-cell lung cancer (NSCLC) who failed the first-line platinum-based chemotherapy. All patients received both sintilimab 200mg and 3×10

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsAntibodies, Monoclonal, HumanizedHumansKiller Cells, NaturalPilot ProjectsPlatinumAntibodies, Monoclonal, HumanizedPlatinumsintilimabimmune cell therapyimmunotherapyNK cellsnon-small cell lung cancerPD1 antibody

Identifiers

PMID36569881
PMCPMC9773193

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.